Oral enzyme combination versus diclofenac in the treatment of osteoarthritis of the knee ? a double-blind prospective randomized study
- 24 July 2004
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 23 (5), 410-415
- https://doi.org/10.1007/s10067-004-0902-y
Abstract
The aim of this study was to compare the efficacy and safety of an oral enzyme-rutosid combination (ERC) containing rutosid and the enzymes bromelain and trypsin, with that of diclofenac in patients with osteoarthritis (OA) of the knee. A total of 103 patients presenting with painful episodes of OA of the knee were treated for 6 weeks in two study centers in a randomized, double-blind, parallel group trial. Altogether, 52 patients were treated in the ERC group and 51 patients were treated in the diclofenac group. Primary efficacy criteria were Lequesne's Algofunctional Index (LFI) and a 'complaint index', including pain at rest, pain on motion and restricted function. The efficacy criteria were analyzed by applying the Wilcoxon-Mann-Whitney test that provides the Mann-Whitney estimator (MW) as a measure of relevance. Non-inferiority was considered to be proven if the lower bound of the 97.5% one-sided confidence interval (CI-LB) was higher than MW = 0.36 (benchmark of not yet relevant inferiority). Both treatments resulted in clear improvements. Within the 6-week observation period, the mean value of the LFI decreased from 13.0 to 9.4 in the ERC group and from 12.5 to 9.4 in the diclofenac group. Non-inferiority of ERC was demonstrated by both primary criteria, LFI (MW = 0.5305; CI-LB = 0.4171) and complaint index (MW = 0.5434; CI-LB = 0.4296). Considerable improvements were also seen in secondary efficacy criteria, with a slight tendency towards superiority of ERC. The global judgment of efficacy by physician resulted in at least good ratings for 51.4% of the ERC patients, and for 37.2% of the diclofenac patients. In the majority of patients tolerability was judged in both drug groups as very good or good. The current study indicates that ERC can be considered as an effective and safe alternative to NSAIDs such as diclofenac in the treatment of painful episodes of OA of the knee. Placebo-controlled studies are now needed to confirm these results.This publication has 14 references indexed in Scilit:
- Clinical evidence for osteoarthritis as an inflammatory diseaseCurrent Rheumatology Reports, 2001
- Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targetsArthritis & Rheumatism, 2001
- A report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria InitiativeOsteoarthritis and Cartilage, 2000
- Vergleichende epidemiologische Studie bei Erkrankungen des rheumatischen Formenkreises am Beispiel der Therapie mit nichtsteroidalen Antiphlogistika versus einem oralen EnzymkombinationspräparatArzneimittelforschung, 2000
- Short-Term Treatment of Painful Osteoarthritis of the Knee with Oral EnzymesClinical Drug Investigation, 2000
- Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Measuring Gain in the Evaluation of Medical Technology The Probability of a Better OutcomeInternational Journal of Technology Assessment in Health Care, 1988
- Nonsteroidal Anti-inflammatory Drug GastropathyArchives of Internal Medicine, 1987
- Indexes of Severity for Osteoarthritis of the Hip and Knee:Validation–Value in Comparison with Other Assessment TestsScandinavian Journal of Rheumatology, 1987